Neffy's Needle-Free Approach and Virtual Access Program Aim to Expand Allergy Emergency Care

NEW YORK, NY – November 04, 2025

Rethinking Emergency Allergy Treatment

ARS Pharmaceuticals launched its “Get neffy on Us” program today, a multifaceted initiative designed to dramatically improve access to its needle-free epinephrine nasal spray, neffy. The program centers on offering free virtual consultations with healthcare providers and the potential for a $0 co-pay for commercially insured patients, marking a departure from traditional epinephrine delivery methods and addressing longstanding barriers to care. While auto-injectors have long been the standard for treating anaphylaxis, ARS Pharma is positioning neffy as a viable and, for some, preferable alternative, particularly for those who fear needles or seek a more discreet option.

“For too long, access to life-saving epinephrine has been hampered by inconvenience and anxiety surrounding traditional delivery methods,” said one industry analyst. “This program acknowledges those concerns and seeks to remove those obstacles, potentially broadening the reach of emergency allergy care.”

Virtual Access and Cost Reduction

The “Get neffy on Us” program's core component is the streamlined virtual consultation process. Patients can connect with a licensed healthcare provider remotely, eliminating the need for an in-person office visit and associated time commitments. This approach is especially appealing to individuals in underserved areas, those with mobility issues, or those who simply prefer the convenience of telehealth. The potential for a $0 co-pay, facilitated through insurance coverage and patient assistance programs, further lowers financial barriers to access.

ARS Pharmaceuticals reports a significant surge in revenue growth, with Q3 2025 revenue reaching $32.5 million, a substantial increase from the $2.1 million reported in the same period last year. While the company is still operating at a net loss, analysts predict robust growth and a pathway to profitability. The “Get neffy on Us” program is viewed as a key driver of this anticipated growth, expanding the patient base and solidifying neffy’s position in the epinephrine market.

“The virtual consultation aspect is a game changer,” explained a healthcare technology consultant. “It removes a significant point of friction for patients who might otherwise delay seeking a prescription. The convenience factor is huge, and the cost savings are substantial.”

Beyond the Auto-Injector: A Growing Market

The epinephrine market is projected to reach $6.41 billion by 2034, with a Compound Annual Growth Rate of 11.42%. While auto-injectors currently dominate this market, neffy represents a growing segment of needle-free alternatives. ARS Pharmaceuticals recently received FDA approval for neffy 1mg, specifically designed for pediatric patients weighing between 33 and 66 pounds, and has expanded availability to select EU countries. The company’s commitment to broadening access extends beyond the “Get neffy on Us” program, with the launch of the neffyInSchools initiative, providing free neffy to K-12 schools across the US.

“There’s a clear demand for alternatives to traditional auto-injectors,” commented a patient advocate. “Many people are simply afraid of needles, and that fear can prevent them from seeking the emergency medication they need. Neffy provides a safe and effective option for those individuals.”

Analysts estimate that over 70% of Type 1 allergy patients are open to utilizing a virtual prescribing option, supporting the viability of the “Get neffy on Us” program. The company's strategic focus on accessibility and innovation positions it as a key player in the evolving landscape of allergy emergency care. The expansion of insurance coverage, including inclusion on Express Scripts Commercial National Formularies, further reinforces neffy’s accessibility to millions of commercially insured patients.

“This isn't just about offering a different product,” stated a pharmaceutical industry analyst. “It’s about rethinking how we deliver emergency allergy care and making it more accessible and convenient for everyone.”